Exploring Noncovalent Protease Inhibitors for the Treatment of Severe Acute Respiratory Syndrome and
Explore the source record for details and available documents.
Freitas, Brendan T.↗
Engineering topics
Tripp, Ralph A.
Publications and source records attributed to Tripp, Ralph A..
Structure, Immunogenicity, and Conformation-Dependent Receptor Binding of the Postfusion Human Metap
Explore the source record for details and available documents.
Huang, Jiachen↗
A Sendai virus recombinant vaccine expressing a gene for truncated human metapneumovirus (hMPV) fusion protein protects cotton rats from hMPV challenge
Human metapneumovirus (hMPV) infections pose a serious health risk to young children, particularly in cases of premature birth. No licensed vaccine exists and there is no standard treatment for hMPV infections apart from supportive hospital care. We describe the production of a Sendai virus (SeV) recombinant that carries a gene for a truncated hMPV fusion (F) protein (SeV-MPV-Ft). The vaccine induces binding and neutralizing antibody responses toward hMPV and protection against challenge with hMPV in a cotton rat system. Results encourage advanced development of SeV-MPV-Ft to prevent the morbidity and mortality caused by hMPV infections in young children. - Highlights: • A Sendai virus-based human metapneumovirus (hMPV) vaccine is being developed. • SeV-MPV-Ft carries a gene for a truncated metapneumovirus fusion protein. • The intranasal vaccine induces hMPV-specific binding antibodies in cotton rats. • The vaccine induces hMPV-specific neutralizing antibodies in cotton rats. • A single immunization protects against hMPV challenge in vivo.
60 APPLIED LIFE SCIENCES↗
Decrease in Formalin-Inactivated Respiratory Syncytial Virus (FI-RSV) Enhanced Disease with RSV G Glycoprotein Peptide Immunization in BALB/c Mice
Respiratory syncytial virus (RSV) is a high priority target for vaccine development. One concern in RSV vaccine development is that a non-live virus vaccine would predispose for enhanced disease similar to that seen with the formalin inactivated RSV (FI-RSV) vaccine. Since a mAb specific to RSV G protein can reduce pulmonary inflammation and eosinophilia seen after RSV infection of FI-RSV vaccinated mice, we hypothesized that RSV G peptides that induce antibodies with similar reactivity may limit enhanced disease after subunit or other non-live RSV vaccines. In support of this hypothesis, we show that FI-RSV vaccinated mice administered RSV G peptide vaccines had a significant reduction in enhanced disease after RSV challenge. These data support the importance of RSV G during infection to RSV disease pathogenesis and suggest that use of appropriately designed G peptide vaccines to reduce the risk of enhanced disease with non-live RSV vaccines merits further study.
59 BASIC BIOLOGICAL SCIENCES↗